Key Points
- Broadwood Partners, L.P. purchased 27,485 shares of STAAR Surgical on Jan. 9 at an average price of $22.05, bringing its direct holdings to 15,453,629 shares (≈$340.8M), a 0.18% increase in ownership.
- This trade is part of a multi-date buying spree by Broadwood (notable large purchases on Jan. 6–8 and Nov. 19–21) totaling millions of dollars and indicating significant accumulation of STAA stock.
- STAAR Surgical has a $1.05B market cap, one‑year range of $13.50–$30.81, a negative P/E (-10.84), very high institutional ownership (96.7%), and a consensus analyst rating of "Reduce" with a $23.42 target.
STAAR Surgical Company (NASDAQ:STAA - Get Free Report) major shareholder Broadwood Partners, L.P. acquired 27,485 shares of the stock in a transaction dated Friday, January 9th. The shares were bought at an average cost of $22.05 per share, with a total value of $606,044.25. Following the completion of the purchase, the insider directly owned 15,453,629 shares in the company, valued at approximately $340,752,519.45. This trade represents a 0.18% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Broadwood Partners, L.P. also recently made the following trade(s):
- On Thursday, January 8th, Broadwood Partners, L.P. bought 3,240 shares of STAAR Surgical stock. The stock was purchased at an average price of $21.94 per share, for a total transaction of $71,085.60.
- On Wednesday, January 7th, Broadwood Partners, L.P. purchased 66,467 shares of STAAR Surgical stock. The shares were purchased at an average cost of $22.00 per share, with a total value of $1,462,274.00.
- On Tuesday, January 6th, Broadwood Partners, L.P. purchased 336,946 shares of STAAR Surgical stock. The shares were purchased at an average price of $21.62 per share, with a total value of $7,284,772.52.
- On Wednesday, November 19th, Broadwood Partners, L.P. acquired 309,132 shares of STAAR Surgical stock. The stock was purchased at an average price of $26.42 per share, for a total transaction of $8,167,267.44.
- On Friday, November 21st, Broadwood Partners, L.P. bought 797,486 shares of STAAR Surgical stock. The shares were purchased at an average price of $27.86 per share, with a total value of $22,217,959.96.
- On Thursday, November 20th, Broadwood Partners, L.P. bought 393,382 shares of STAAR Surgical stock. The shares were acquired at an average cost of $27.14 per share, with a total value of $10,676,387.48.
STAAR Surgical Stock Performance
NASDAQ STAA opened at $21.13 on Wednesday. STAAR Surgical Company has a one year low of $13.50 and a one year high of $30.81. The company's 50 day moving average price is $24.87 and its 200 day moving average price is $24.58. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -10.84 and a beta of 1.00.
Institutional Investors Weigh In On STAAR Surgical
A number of hedge funds have recently bought and sold shares of STAA. CWM LLC increased its holdings in STAAR Surgical by 74.1% during the 2nd quarter. CWM LLC now owns 1,563 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 665 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of STAAR Surgical by 2,605.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier's stock worth $28,000 after buying an additional 1,016 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of STAAR Surgical by 61.4% in the third quarter. GAMMA Investing LLC now owns 1,856 shares of the medical instruments supplier's stock worth $50,000 after buying an additional 706 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in STAAR Surgical by 691.0% in the second quarter. PNC Financial Services Group Inc. now owns 3,607 shares of the medical instruments supplier's stock valued at $61,000 after acquiring an additional 3,151 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in STAAR Surgical by 375.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier's stock valued at $99,000 after acquiring an additional 4,673 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on STAA. Needham & Company LLC reiterated a "hold" rating on shares of STAAR Surgical in a report on Tuesday, January 6th. Canaccord Genuity Group increased their target price on STAAR Surgical from $28.00 to $30.75 and gave the company a "hold" rating in a research note on Tuesday, December 9th. BTIG Research reissued a "neutral" rating on shares of STAAR Surgical in a research report on Tuesday, January 6th. Wells Fargo & Company upped their price target on STAAR Surgical from $28.00 to $30.75 and gave the stock an "equal weight" rating in a report on Wednesday, December 10th. Finally, Piper Sandler reiterated a "neutral" rating on shares of STAAR Surgical in a research note on Monday, October 27th. Ten equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Reduce" and a consensus target price of $23.42.
Get Our Latest Report on STAAR Surgical
STAAR Surgical Company Profile
(
Get Free Report)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
